MedCity News April 18, 2024
Arundhati Parmar

A much diminished 23andMe exists today, a far cry from the phenomenon that it was in the world consumer DNA testing. Could things have unfolded differently under a different leader with a different vision?

Back in January, I was invited to a J.P. Morgan reception hosted by 23andMe, the storied gene testing company that Anne Wojcicki runs as co-founder and CEO.

Standing on the topmost floor of the Salesforce tower with 360-degree views of the city below — far from the tents and the grime of the downtown sidewalks — I was struck by how sparkling San Francisco is on a clear, fogless night. I wordlessly thanked whoever put me on the invitee list affording me the chance to savor...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Pharma / Biotech, Precision Medicine
Ohio State to Launch Precision Medicine Initiative With Helix
Million Veteran Program Bridges Diversity Gap in Genome-Wide Association Studies
Massive study of veterans’ DNA shows how diversity can help researchers decipher the genome
Breakthrough interactive atlas offers pathway to precision medicine for TBI patients
Charting an equitable future for DNA and ancient DNA research in Africa

Share This Article